Description  Claims  Drawing  Cited references 

WO2014110372A   [0006] 
WO2013022797A   [0006] 
WO2009002529A2   [0192]  [0199]  [0199] 
WO2010108125A2   [0192]  [0199] 
US2008007947W   [0199] 
US2010028020W   [0199] 
US2008013158W   [0199] 
WO2009070302A1   [0199] 
US20130034494A1   [0199] 
WO2011106639A   [0199] 
WO2010045598A2   [0199] 
WO2009026177A1   [0199] 

MRI Detection of VEGFR2 in Vivo Using a Low Molecular Weight Peptoid-(Gd)8-Dendron for Targeting   [0006] 
Synthesis and Evaluation of a Peptide Targeted Small Molecular Gd-DOTA Monoamide Conjugate for MR Molecular Imaging of Prostate Cancer   [0006] 
Greene's Protective Groups in Organic Synthesis   [0114] 
The Science and Practice of Pharmacy   [0117] 
Pharmaceutical Salts   [0119] 
Curr Pharm Biotechnol   [0199] 
Molecular magnetic resonance imaging with targeted contrast agents   [0199] 
Magn Reson Med   [0199] 
Cancer Res   [0199] 
Radiolabeled prostate specific membrane antigen inhibitors   [0199] 
Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy   [0199] 
Phase I trial of lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer   [0199] 
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)   [0199] 
Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer   [0199] 
Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen   [0199] 
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)   [0199] 
Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA)   [0199] 
64Cu-Labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer   [0199] 
Preclinical evaluation of Y-labeled inhibitors of prostate specific membrane antigen for dosimetry estimates   [0199] 
Synthesis, radiolabelling and in vitro characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-labelled PSMA ligand, CHX-A''-DTPA-DUPA-Pep   [0199] 
Nanoscale   [0199] 
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours   [0199] 
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature   [0199] 
J Am Chem Soc   [0199] 
Inorg Chem   [0199] 
Contrast Media Mol Imaging   [0199] 
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)   [0199] 
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb   [0199] 
PSMA-targeted theranostic nanoplex for prostate cancer therapy   [0199] 
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction   [0199] 
Biodistribution, tumor detection, and radiation dosimetry of F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer   [0199] 
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals   [0199] 
MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting   [0199] 
Proc Natl Acad Sci USA   [0199] 
Invest Radiol   [0199] 
Contrast Media Mol Imaging   [0199] 
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer   [0199] 
Hum Pathol   [0199] 
Mod Pathol   [0199] 
Magn Reson Imaging   [0199] 
Pre-therapeutic dosimetry and biodistribution of Y-DOTAPhe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours   [0199] 
J Nucl Med   [0199] 
I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison   [0199] 
Curr Top Med Chem   [0199] 
Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides   [0199] 
Lutetium-labelled peptides for therapy of neuroendocrine tumours   [0199] 
Magma   [0199] 
First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer   [0199] 
JNucl Cardiol   [0199] 
Radioimmunotherapy for model B cell malignancies using Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies   [0199] 
Acc Chem Res   [0199] 
A modular system for the synthesis of multiplexed magnetic resonance probes   [0199] 
Radioimmunotherapy with alpha-emitting nuclides   [0199] 
PET imaging in prostate cancer: focus on prostate-specific membrane antigen   [0199] 
Vascular targeted therapy with anti-prostatespecific membrane antigen monoclonal antibody J591 in advanced solid tumors   [0199] 
Y based PET radiopharmaceuticals: radiochemistry and biological applications   [0199] 
Clinical trials of cancer therapies targeting prostate specific membrane antigen   [0199] 
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR   [0199] 
Pharmacokinetics and biodistribution of (86)Ytrastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI   [0199] 
Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents   [0199] 
Magn Reson Med   [0199] 
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy   [0199] 
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody   [0199] 
Prostate-specific membrane antigen expression in normal and malignant human tissues   [0199] 
JAm Chem Soc   [0199] 
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine   [0199] 
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer   [0199] 
Phase II study of Lutetium-177-labeled anti-prostate specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer   [0199] 
Nanomedicine   [0199] 
Pharmacokinetics and biodistribution of In- and Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of YJ591 radiation dosimetry based on In or Lu   [0199] 
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma   [0199] 
Letter: Expression of tissue isotope distribution   [0199] 
Bioconjug Chem   [0199] 
Towards translation of 212Pb as a clinical therapeutic; getting the lead in   [0199] 
212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease   [0199] 
212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint   [0199] 
Preparation of high specific activity (86)Y using a small biomedical cyclotron   [0199] 
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy   [0199]